As AML patients with MLL-PTD even received intensive therapy such as stem cell transplantation still died of the disease, novel target therapy and tailored treatment according to their concomitant genetic aberrations will hold promise to improve the outcome of patients with MLL-PTD associated AML. This evidence concerns the gene KMT2A and acute myeloid leukemia.